Analyses for criteria when applied at baseline | Analyses for criteria when applied during follow-up | |||||||
---|---|---|---|---|---|---|---|---|
DMARD use | Methotrexate use | DMARD use | Methotrexate use | |||||
2010 Criteria | 1987 Criteria | 2010 Criteria | 1987 Criteria | 2010 Criteria | 1987 Criteria | 2010 Criteria | 1987 Criteria | |
Sensitivity (%) | 62 | 38 | 68 | 42 | 68 | 80 | 74 | 87 |
Specificity (%) | 78 | 93 | 72 | 88 | 73 | 81 | 66 | 70 |
Positive predictive value (%) | 75 | 85 | 57 | 66 | 73 | 81 | 55 | 63 |
Negative predictive value (%) | 66 | 59 | 81 | 73 | 69 | 79 | 82 | 91 |
Positive likelihood ratio | 2.81 | 5.44 | 2.44 | 3.50 | 2.17 | 3.87 | 3.14 | 6.94 |
Negative likelihood ratio | 0.49 | 0.67 | 0.44 | 0.65 | 0.46 | 0.26 | 0.25 | 0.11 |
ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism.